Abstract
A recent report in this year's April issue of Journal of the American Medical Association describes an unprecedented success in delaying insulin dependence in patients with recent-onset Type 1 diabetes after non-myeloablative immune suppression with cyclophosphamide and antithymocyte globulin followed by autologous stem cell transplantation. In this study, 14 out of 15 patients became insulin-independent, which lasted up to 35 months. Concomitantly, C-peptide levels increased substantially compared with preintervention values. Treatment of autoimmune disorders, and in particular Type 1 diabetes, constitutes a complex balancing act between suppressing autoaggressive responses strongly and permanently enough, while circumventing much-feared long-term side effects from chronic immunosuppression. This clinical Phase I/II trial is relevant to fine-tuning interventive protocols and contributing to the further development of suitable combination therapies to prevent and treat Type 1 diabetes.
| Original language | English |
|---|---|
| Pages (from-to) | 845-851 |
| Number of pages | 7 |
| Journal | Regenerative Medicine |
| Volume | 2 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Sep 2007 |
Fingerprint
Keywords
- Anti-CD3
- Anti-thymocyte globulin
- Cyclophosphamide
- Diabetes
- Human trial
- Non-myeloablative stem cell transplantation
- Tregs
ASJC Scopus subject areas
- Biomedical Engineering
- Embryology
Cite this
Stopping diabetes in its tracks : Autologous non-myeloablative stem cell transplantation. / Fousteri, Georgia; Hayek, Alberto; von Herrath, Matthias.
In: Regenerative Medicine, Vol. 2, No. 5, 09.2007, p. 845-851.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Stopping diabetes in its tracks
T2 - Autologous non-myeloablative stem cell transplantation
AU - Fousteri, Georgia
AU - Hayek, Alberto
AU - von Herrath, Matthias
PY - 2007/9
Y1 - 2007/9
N2 - A recent report in this year's April issue of Journal of the American Medical Association describes an unprecedented success in delaying insulin dependence in patients with recent-onset Type 1 diabetes after non-myeloablative immune suppression with cyclophosphamide and antithymocyte globulin followed by autologous stem cell transplantation. In this study, 14 out of 15 patients became insulin-independent, which lasted up to 35 months. Concomitantly, C-peptide levels increased substantially compared with preintervention values. Treatment of autoimmune disorders, and in particular Type 1 diabetes, constitutes a complex balancing act between suppressing autoaggressive responses strongly and permanently enough, while circumventing much-feared long-term side effects from chronic immunosuppression. This clinical Phase I/II trial is relevant to fine-tuning interventive protocols and contributing to the further development of suitable combination therapies to prevent and treat Type 1 diabetes.
AB - A recent report in this year's April issue of Journal of the American Medical Association describes an unprecedented success in delaying insulin dependence in patients with recent-onset Type 1 diabetes after non-myeloablative immune suppression with cyclophosphamide and antithymocyte globulin followed by autologous stem cell transplantation. In this study, 14 out of 15 patients became insulin-independent, which lasted up to 35 months. Concomitantly, C-peptide levels increased substantially compared with preintervention values. Treatment of autoimmune disorders, and in particular Type 1 diabetes, constitutes a complex balancing act between suppressing autoaggressive responses strongly and permanently enough, while circumventing much-feared long-term side effects from chronic immunosuppression. This clinical Phase I/II trial is relevant to fine-tuning interventive protocols and contributing to the further development of suitable combination therapies to prevent and treat Type 1 diabetes.
KW - Anti-CD3
KW - Anti-thymocyte globulin
KW - Cyclophosphamide
KW - Diabetes
KW - Human trial
KW - Non-myeloablative stem cell transplantation
KW - Tregs
UR - http://www.scopus.com/inward/record.url?scp=35048846482&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35048846482&partnerID=8YFLogxK
U2 - 10.2217/17460751.2.5.845
DO - 10.2217/17460751.2.5.845
M3 - Article
C2 - 17907936
AN - SCOPUS:35048846482
VL - 2
SP - 845
EP - 851
JO - Regenerative Medicine
JF - Regenerative Medicine
SN - 1746-0751
IS - 5
ER -